ArticleInternational journal of women's health2026
Development and Validation of a Combined 2D-US and CDUS Nomogram for Differentiating Benign and Malignant Breast Masses: A Retrospective Study.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the differential imaging features of benign and malignant breast masses using two-dimensional ultrasonography (2D-US) and color Doppler ultrasonography (CDUS) and to develop a combined imaging-based predictive nomogram for risk stratification of malignancy. Methods: A single-center retrospective study was conducted, analyzing 258 patients with breast masses who underwent 2D-US and CDUS and had definitive pathological diagnoses between May 2023 and June 2025, including 177 benign and 81 malignant cases. Demographic and imaging characteristics were compared between the two groups. Independent predictors of malignancy were identified using multivariate logistic regression, based on which a predictive nomogram was constructed. Model performance and calibration were evaluated using receiver operating characteristic (ROC) curve analysis, the Hosmer-Lemeshow goodness-of-fit test, and bootstrap resampling. Results: Patients in the malignant were older and exhibited larger tumor diameters and higher Breast Imaging Reporting and Data System (BI-RADS) categories. On 2D-US, irregular morphology, indistinct boundary, lobulated or spiculated margin, and microcalcifications. CDUS revealed significantly higher Adler grades in the malignant cases. Age, tumor diameter, BI-RADS category, morphology, boundary, margin, and Adler grade were independent predictors of malignancy. The combined imaging nomogram demonstrated an area under the ROC curve (AUC) of 0.926 (95% confidence interval [CI]: 0.892-0.959), with 83.95% sensitivity and 89.27% specificity, showing good calibration and discriminatory ability. Conclusion: The developed nomogram integrating 2D-US and CDUS imaging features provides good discriminatory performance and risk stratification capability for differentiating benign from malignant breast masses. These findings support its potential utility in clinical decision-making, although external validation in independent cohorts is warranted to confirm generalizability.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.